A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
NCT ID: NCT00864981
Last Updated: 2017-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
2005-09-30
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
NCT00749658
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
NCT00181818
Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking
NCT00248118
Comparative Study of SR Bupropion for Adolescent Smoking Cessation
NCT00819078
Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers
NCT00133757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Bupropion HCI ER Tablets, 150 mg
Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
2
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shirley A Kennedy, M.D.
Role: PRINCIPAL_INVESTIGATOR
Novum Pharmaceutical Research Services
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B052005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.